0001209191-22-036137.txt : 20220610 0001209191-22-036137.hdr.sgml : 20220610 20220610195129 ACCESSION NUMBER: 0001209191-22-036137 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220608 FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hallal David CENTRAL INDEX KEY: 0001457477 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 221010408 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS, INC STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET STREET 2: BLDG 312, FLOOR 3, SUITE 301 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET STREET 2: BLDG 312, FLOOR 3, SUITE 301 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-08 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001457477 Hallal David C/O ITEOS THERAPEUTICS, INC. 321 ARSENAL STREET WATERTOWN MA 02472 1 0 0 0 Common Stock 2022-06-08 4 M 0 5968 4.23 A 5968 D Common Stock 2022-06-08 4 S 0 5968 20.39 D 0 D Common Stock 2022-06-08 4 M 0 11899 2.95 A 11899 D Common Stock 2022-06-08 4 S 0 11899 20.39 D 0 D Common Stock 2022-06-08 4 M 0 10577 4.23 A 10577 D Common Stock 2022-06-08 4 S 0 10577 19.86 D 0 D Common Stock 2022-06-09 4 M 0 1171 4.23 A 1171 D Common Stock 2022-06-09 4 S 0 1171 19.51 D 0 D Stock Option (Right to Buy) 4.23 2022-06-08 4 M 0 5968 0.00 D 2030-05-01 Common Stock 5968 157908 D Stock Option (Right to Buy) 2.95 2022-06-08 4 M 0 11899 0.00 D 2029-12-04 Common Stock 11899 25140 D Stock Option (Right to Buy) 4.23 2022-06-08 4 M 0 10577 0.00 D 2030-05-01 Common Stock 10577 147331 D Stock Option (Right to Buy) 4.23 2022-06-09 4 M 0 1171 0.00 D 2030-05-01 Common Stock 1171 146160 D Stock Option (Right to Buy) 18.78 2022-06-09 4 A 0 17538 0.00 A 2032-06-09 Common Stock 17538 17538 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.12, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.37 to $19.62, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date. This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders. /s/ Adi Osovsky, as Attorney-in-Fact 2022-06-10